^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA: Preferred Regimens...High-dose methotrexate….combined with…Rituximab and TMZ...
    Secondary therapy:
    methotrexate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA: Other Recommended Regimens...Lenalidomide with or without rituximab
    Secondary therapy:
    lenalidomide
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA : Preferred Regimen... Rituximab